TABLE 1.
Baseline anthropometric and clinical characteristics of the patients completing the trial
| Total study population (n = 23) | |
|---|---|
| Female/male (n) | 8/15 |
| Age (y) | 55.5 ± 8 |
| BMI (kg/m2) | 31.2 ± 4.2 |
| Waist circumference (cm) | 107.2 ± 9 |
| Systolic blood pressure (mmHg) | 127 ± 13 |
| Diastolic blood pressure (mmHg) | 80 ± 11 |
| Heart rate (bpm) | 74 ± 10 |
| Fasting glucose (mg/dl) | 149 ± 25 |
| Fasting plasma insulin (mU/ml) | 10.7 ± 6.2 |
| HbA1c (%) (mmol/mol) |
7.5 ± 1 (58 ± 7.6) |
| Total cholesterol (mg/dl) | 176 ± 36 |
| LDL cholesterol (mg/dl) | 112 ± 24 |
| HDL cholesterol (mg/dl) | 45 ± 9 |
| Triglycerides (mg/dl) | 143 ± 69 |
| Insulin‐stimulated glucose disposal corrected for fat‐free mass (mg/min × kg FFM) | 3.8 ± 2.4 |
| Myocardial MrGlu (μmol/min/100 g) | 14.1 ± 9 |
| Diabetes duration (y) | 5.6 ± 5 |
| Hypertension (%) | 65 |
| Lipid‐lowering therapy (%) | 61.5 |
| Antihypertensive therapy (%) | 65.4 |
Note: Data are means ± SD.
Abbreviations: BMI, body mass index; FFM, fat‐free mass; MrGlu, glucose metabolic rate.